These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 62790)

  • 21. Antigenic identification of chemotactic factor inactivator in normal human serum and bronchoalveolar lavage fluid.
    Robbins RA; Rasmussen JK; Clayton ME; Gossman GL; Kendall TJ; Rennard SI
    J Lab Clin Med; 1987 Sep; 110(3):292-9. PubMed ID: 3611952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical quantitation of the chemotactic factor inactivator activity in human serum.
    Fantone J; Senior RM; Kreutzer DL; Jones M; Ward PA
    J Lab Clin Med; 1979 Jan; 93(1):17-24. PubMed ID: 759526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neutropenia induced by systemic infusion of chemotactic factors.
    O'Flaherty JT; Showell HJ; Ward PA
    J Immunol; 1977 May; 118(5):1586-9. PubMed ID: 858915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of human C 1 inhibitor on complement-mediated human leukocyte chemotaxis.
    Smith CW; Hollers JC; Bing DH; Patrick RA
    J Immunol; 1975 Jan; 114(1 Pt 1):216-20. PubMed ID: 1167560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
    Perez HD; Lipton M; Goldstein IM
    J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.
    Orr FW; Mokashi S; Delikatny J
    Am J Pathol; 1982 Jul; 108(1):112-8. PubMed ID: 7091299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide.
    Shingu M; Nobunaga M
    Am J Pathol; 1984 Nov; 117(2):201-6. PubMed ID: 6388344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement-derived leukotactic factors in inflammatory synovial fluids of humans.
    Ward PA; Zvaifler NJ
    J Clin Invest; 1971 Mar; 50(3):606-16. PubMed ID: 5545123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of the chemotactic activity of human C5a des Arg by an anionic polypeptide ("cochemotaxin") in normal serum and plasma.
    Perez HD; Goldstein IM; Webster RO; Henson PM
    J Immunol; 1981 Feb; 126(2):800-4. PubMed ID: 7451994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles of IgG, IgM rheumatoid factor, and their complexes in the induction of polymorphonuclear leukocyte chemotactic factor from complement.
    Wagner T; Abraham G; Baum J
    J Clin Invest; 1974 Jun; 53(6):1503-11. PubMed ID: 4133792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes.
    O'Flaherty JT; Kreutzer DL; Ward PA
    Am J Pathol; 1978 Mar; 90(3):537-50. PubMed ID: 564610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective leukotaxis in patients with lepromatous leprosy.
    Ward PA; Goralnick S; Bullock WE
    Int J Lepr Other Mycobact Dis; 1976; 44(1-2):243-9. PubMed ID: 945238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A leukotactic factor in the stratum corneum of pustulosis palmaris et plantaris: a possible mechanism for the formation of intra-epidermal sterile pustules.
    Tagami H; Ofuji S
    Acta Derm Venereol; 1978; 58(5):401-5. PubMed ID: 82349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the anaphylatoxin inactivator and chemotactic factor inactivator activities during cardiopulmonary bypass.
    Kreutzer DL; McCormick JR; Despins A; Moore M; Rousou JH; Dobbs W; Engleman RN
    J Exp Pathol; 1984; 1(3):183-7. PubMed ID: 6336305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonspecific activation of complement factor 5 by isolated Dermacentor andersoni salivary antigens.
    Gordon JR; Allen JR
    J Parasitol; 1991 Apr; 77(2):296-301. PubMed ID: 2010863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibitory effect of chemotactic factors on erythrophagocytosis by human neutrophils.
    Musson RA; Becker EL
    J Immunol; 1976 Aug; 117(2):433-9. PubMed ID: 781130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chemotactic activity in the fluid of bullous pemphigoid blisters].
    Diáz Pérez JL; Jordon RE
    Med Cutan Ibero Lat Am; 1975; 3(6):465-70. PubMed ID: 778510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C3 leukotactic factors produced by a tissue protease.
    Hill JH; Ward PA
    J Exp Med; 1969 Sep; 130(3):505-18. PubMed ID: 4185247
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human monocyte adherence: a primary effect of chemotactic factors on the monocyte to stimulate adherence to human endothelium.
    Doherty DE; Haslett C; Tonnesen MG; Henson PM
    J Immunol; 1987 Mar; 138(6):1762-71. PubMed ID: 3819394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.